Up­dat­ed: Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

Oc­to­ber and No­vem­ber were crit­i­cal months in shap­ing the fu­ture of the UK’s bio­phar­ma sec­tor. Af­ter sev­er­al years of macro­eco­nom­ic chal­lenges, the gov­ern­ment un­veiled a bun­dle of new drug pric­ing, reg­u­la­to­ry and fi­nan­cial mea­sures in the fourth quar­ter aimed at in­creas­ing the at­trac­tive­ness of its health­care sys­tem to both in­dus­try and in­vestors at lo­cal and glob­al lev­els.

For starters, the UK re­cent­ly re­freshed its ap­proach to drug pric­ing in a bid to save its NHS mon­ey while al­so boost­ing the com­pet­i­tive­ness of its drugs mar­ket. The UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency (MHRA) has al­so made moves to ad­dress how long com­pa­nies wait for clin­i­cal tri­al au­tho­riza­tions. And, just last month, chan­cel­lor Je­re­my Hunt un­veiled a pack­age of new eco­nom­ic com­mit­ments aimed at “un­lock­ing growth and pro­duc­tiv­i­ty” in the home­grown life sci­ence space.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.